AI market research for pharma and rare disease.
In rare disease, a study can wait months for a dozen patients. Jean turns each interview you do get into a digital twin, so the team can keep asking questions between waves.
Interviewed over 5 weeks through two advocacy groups and specialist referrals.
Asked of all 24 twins
“What would hold you back from switching to the new therapy?”
GapCaregivers name the infusion day almost every time. Specialists almost never do.
“Every other Tuesday I lose a day of pay to drive him there and sit for six hours.”Caregiver twin, spouse
Next: confirm with 8 real caregiver interviews, by voice, overnight.
Rare disease patients, caregivers and specialists, without the recruiting wait.
What teams run
Each study starts with a question like one of these.
Rare disease patient and caregiver research
“What happened in the years between first symptoms and a diagnosis?”
HCP message testing
“Which claim would make a specialist consider switching a stable patient?”
Treatment decision research
“Who in the family decides whether to start a new therapy, and what do they weigh?”
Patient support program research
“Where do patients drop off between the prescription and the first infusion?”
Adherence and persistence
“Why do patients stop treatment in the third month?”
Make every rare interview count twice.
Each patient, caregiver or specialist you interview becomes a digital twin. Ask the panel new questions in minutes, with no new recruit and no new burden on the patient. Then confirm what matters with real people.
See where patients, caregivers and doctors disagree.
Ask the same question to each group and compare the answers side by side. The gaps between what a specialist assumes and what a family lives with are often the finding.
Interview at the patient's pace, in their language.
The interviewer runs by text or voice, around the clock, and can pause when someone is tired. A caregiver can answer after bedtime and a neurologist between clinics. Full transcripts go to your team for safety review.
How you run it
- 1Minutes
Screen
A thousand digital twins answer first, so the weak options drop out.
- 2Overnight
Interview
The AI interviewer talks to real people and follows up on what they say.
- 3By morning
Decide
The number, the reasons behind it and the quotes that carry it.
Questions
How do digital twins help rare disease market research?
Each twin is built from a real interview with a patient, caregiver or specialist. Once you have a panel, you can test new questions, messages and materials on it in minutes, without going back to a small and tired patient community. Use the twins to narrow the options, then confirm the winners with real interviews.
Can digital twins replace real patients?
No. A twin can only reflect people like the ones it was built from, and in rare disease that panel is small. Treat twin answers as a fast first read and confirm decisions with real patients and clinicians.
Can Jean interview HCPs and specialists?
Yes. Jean interviews physicians, nurses, pharmacists and other HCPs, recruited to your spec or invited from your own lists. Interviews run by text or voice, so a specialist can answer between clinics.
How are adverse events handled in AI-moderated interviews?
Pharma market research usually has to report adverse events under the sponsor's pharmacovigilance process and guidelines such as EphMRA's. Every Jean interview produces a full transcript, so your safety team can review it under your process. Agree the reporting plan with us before fieldwork.
Is Jean HIPAA certified?
No, and no official HIPAA certification exists. Market research rarely needs medical records, so we recommend designing studies that collect no protected health information. If yours needs more, talk to us before you start.
Can our agency offer this to pharma clients?
Yes. Healthcare research agencies and panel companies resell Jean's AI interviewer and digital twins under their own brand. Jean runs the technology; you keep the client, the method and the margin.